腹膜炎患者预防性植入生物补片(PROPHYBIOM):一项前瞻性多中心随机对照试验
本研究为前瞻性多中心随机对照试验,计划纳入90例因腹膜炎在污染/感染术野行急诊剖腹术的患者,随机分为预防性腹膜前放置猪真皮胶原补片组与常规腹壁缝合组,术后3、6、12个月随访,通过体格检查与超声评估切口疝发生率、伤口感染及不良事件。
要点
- 腹膜炎急诊手术患者切口疝风险极高,术后腹壁并发症增加发病率、死亡率和住院时间。
- 试验计划纳入90例患者,随机分为预防性猪真皮胶原补片腹膜前放置组与常规腹壁缝合组。
- 术后3、6、12个月随访,用体格检查和超声评估切口疝、伤口感染及不良事件。
核心结论
- 目的是评估在污染/感染术野因腹膜炎行急诊/紧急剖腹术的患者中,预防性腹膜前放置猪真皮胶原补片能否降低切口疝发生率。
研究设计与样本
- 前瞻性多中心随机对照试验,计划样本量为90例患者,分为补片放置组与常规腹壁缝合组两臂。
- 随访时间为术后3、6、12个月,通过体格检查和超声评估切口疝百分比、伤口感染和不良事件。
- 试验注册于ClinicalTrials.gov(NCT04681326),于2020年12月23日注册(首例患者入组后回顾性注册)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients undergoing emergency surgery for peritonitis are at increased risk of abdominal wall-related complications. In patients with peritonitis, the risk of incisional hernia (IH) is extremely elevated. The evaluation of quality of life of patients with incisional hernia showed lower mean scores on physical components of health-related quality of life and body image. Furthermore, the arise of a post-operative abdominal wall complication (i.e., wound dehiscence, evisceration and IH) greatly increases morbidity and mortality rates and prolongs the hospitalization. METHODS: The present study aims to evaluate the efficacy of the use of a swine dermal collagen prosthesis implanted preperitoneally as a prophylactic procedure in urgency/emergency setting against abdominal wall complications in patients operated with contaminated/infected field in peritonitis. The sample size was defined in 90 patients divided in two arms (prosthesis positioning versus normal wall abdominal closure). The follow-up will be performed at 3, 6, and 12 months after surgery. The percentage of incisional hernias, wound infections, and adverse events will be investigated by physical examination and ultrasound. DISCUSSION: The objective is to evaluate the possibility to reduce the incisional hernia rate in patients undergoing urgent/emergent laparotomy in contaminated/infected field with peritonitis by using swine dermal collagen prosthesis preperitoneal positioning as a prophylactic procedure. TRIAL REGISTRATION: ClinicalTrials.gov NCT04681326. Registered (retrospectively after first patient recruited) on 23 December 2020.
引用
- Coccolini F, Tarasconi A, Petracca GL, et al. PROPHYlactic Implantation of BIOlogic Mesh in peritonitis (PROPHYBIOM): a prospective multicentric randomized controlled trial. Trials. 2022. PMID: 35246206. doi:10.1186/s13063-022-06103-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。